Related Experiment Video
Updated: Jun 25, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with
Christina A Von Roemeling1, Bently P Doonan2, Savannah L Carpenter1
1University of Florida Gainesville, FL United States.
Abstract:
Current advances in the treatment of melanoma brain metastases through immune checkpoint blockade and targeted therapy has significantly improved outcomes and patient survival. Yet, half of all patients continue to die from brain metastases despite use of these therapies and the addition of localized therapies like surgery and stereotactic radiosurgery. Novel treatments are needed to improve the morbidity and mortality associated with melanoma brain metastases. We have identified the inflammatory myddosomal pathway as a novel potential target of therapy in melanoma brain metastases, with gross upregulation in both tumor tissue and tumor-infiltrating immune cells. These cells display upregulation in MYD88, IRAK-1, IRAK-4, and downstream mediators of inflammatory activation at both the gene and protein level. We have previously shown the ability of the oral IRAK-4 inhibitor emavusertib (CA-4948) to penetrate the blood brain barrier and inhibit the myddosomal pathway in metastatic melanoma and primary CNS lymphoma. In this study we further show the capacity for IRAK-4 inhibition with emavusertib to improve the therapeutic efficacy of anti-PD-1 immune checkpoint blockade in melanoma brain metastases. Emavusertib in combination with anti-PD-1 therapy results in improved tumor-infiltrating lymphocyte recruitment, decreased myeloid derived suppressor cell function, and upregulation of interferon γ signaling resulting in improved survival in aggressive mouse models of melanoma brain metastases. This work supports the development of combination strategies of emavusertib with immune checkpoint blockade in melanoma brain metastases.
Insights
Targeting the inflammatory myddosomal pathway with emavusertib enhances anti-PD-1 therapy for melanoma brain metastases. This combination improves immune cell function and survival in aggressive models, offering a novel treatment strategy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Melanoma brain metastases remain a significant cause of mortality despite current treatments.
- Novel therapeutic strategies are crucial to improve outcomes for patients with melanoma brain metastases.
Purpose of the Study:
- To investigate the inflammatory myddosomal pathway as a therapeutic target in melanoma brain metastases.
- To evaluate the efficacy of combining the IRAK-4 inhibitor emavusertib with anti-PD-1 immune checkpoint blockade.
Main Methods:
- Analysis of myddosomal pathway components (MYD88, IRAK-1, IRAK-4) in melanoma brain metastases.
- Assessment of emavusertib's ability to cross the blood-brain barrier and inhibit the myddosomal pathway.
- Evaluation of combination therapy (emavusertib + anti-PD-1) in aggressive mouse models of melanoma brain metastases.
Main Results:
- The myddosomal pathway is upregulated in melanoma brain metastases and associated immune cells.
- Emavusertib penetrates the blood-brain barrier and inhibits the myddosomal pathway.
- Combination therapy enhanced anti-PD-1 efficacy by increasing tumor-infiltrating lymphocytes, reducing myeloid-derived suppressor cells, and upregulating interferon-γ signaling, leading to improved survival.
Conclusions:
- The inflammatory myddosomal pathway is a promising therapeutic target for melanoma brain metastases.
- Combining emavusertib with anti-PD-1 immune checkpoint blockade demonstrates significant therapeutic potential.
- This combination strategy warrants further development for treating melanoma brain metastases.
